Nanobiotix S.A. logo
Nanobiotix S.A. NBTX
$ 31.34 3.28%

Annual report 2025
added 04-11-2026

report update icon

Nanobiotix S.A. Financial Statements 2011-2026 | NBTX

Annual Financial Statements Nanobiotix S.A.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - - - 262 B 405 M - - - - - - - - -

Shares

- - - - 34.7 B 24.4 M - - - - - - - - -

Historical Prices

30.3 3.27 5.74 8.22 7.54 16.6 - - - - - - - - -

Net Income

- - - - -47 M -33.6 M -50.9 M -30.3 M -26.1 M -21.9 M -17 M -9.56 M -8.14 M -5.33 M -5.25 M

Revenue

32.6 M -7.19 M 36.2 M 4.78 M 2.65 M 2.51 M 2.54 M 3.48 M 252 K 1.56 M 266 K 968 K 185 K 74.2 K 1.36 M

Operating Income

- - - - -52.6 M -36.4 M -46.8 M -30.1 M - - - - - - -

Interest Expense

- - - - - -4.68 M 4.43 M 847 K - - - - - - -

EBITDA

- - - - -52.6 M -36.4 M -46.8 M -30.1 M -25.3 M -21.8 M -17.1 M -9.6 M -8.04 M -5.15 M -3.79 M

Operating Expenses

43.4 M 61.2 M 63 M 51.5 M 55.2 M 38.9 M 49.3 M 33.5 M - - - - - - -

General and Administrative Expenses

- - - - 19.4 M - - - - - - - - - -

All numbers in EUR currency

Quarterly Income Statement Nanobiotix S.A.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

All numbers in EUR currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Nanobiotix S.A. NBTX
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Nanobiotix S.A. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
BioNTech SE BioNTech SE
BNTX
$ 97.54 2.14 % $ 27.2 B germanyGermany
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 8.65 8.19 % $ 85.5 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.63 -2.42 % $ 8.73 B australiaAustralia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 2.14 -1.38 % $ 445 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.81 -0.07 % $ 27.9 M israelIsrael
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 20.47 0.49 % $ 957 M usaUSA
Genmab A/S Genmab A/S
GMAB
$ 28.2 -0.18 % $ 18 B danmarkDanmark
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.19 -0.24 % $ 6.83 B spainSpain
GT Biopharma GT Biopharma
GTBP
$ 0.36 -2.82 % $ 1.98 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Halozyme Therapeutics Halozyme Therapeutics
HALO
$ 67.06 -1.12 % $ 8.04 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 28.69 -0.69 % $ 1.65 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.41 0.71 % $ 363 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.96 1.37 % $ 4.87 M israelIsrael
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.16 1.84 % $ 445 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.01 -0.85 % $ 3.05 B usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 7.12 1.14 % $ 64.3 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 32.24 - $ 2.14 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.48 -0.67 % $ 394 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Immatics N.V. Immatics N.V.
IMTX
$ 10.48 0.43 % $ 659 M germanyGermany
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Incyte Corporation Incyte Corporation
INCY
$ 94.86 -1.26 % $ 18.5 B usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.61 2.35 % $ 16.4 M usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.05 4.5 % $ 152 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Inventiva S.A. Inventiva S.A.
IVA
$ 5.18 -1.52 % $ 138 M franceFrance